To characterize the immunotherapeutic activity of SR9243, we FACs-profiled tumor-infiltrating and lymph node resident DCs, myeloid-derived suppressor cells (MDSCs), CD8+ T-cells and Tregs from tumor-bearing C57BL6J mice treated with SR9243. Here, CD8A is linked to neoplasm.